These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 39097431)

  • 21. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
    Tajiri K; Aonuma K; Sekine I
    Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
    Yeh ET; Tong AT; Lenihan DJ; Yusuf SW; Swafford J; Champion C; Durand JB; Gibbs H; Zafarmand AA; Ewer MS
    Circulation; 2004 Jun; 109(25):3122-31. PubMed ID: 15226229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse Events in Cancer Immunotherapy.
    Abdel-Wahab N; Alshawa A; Suarez-Almazor ME
    Adv Exp Med Biol; 2017; 995():155-174. PubMed ID: 28321817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardio-oncology: management of cardiovascular toxicity.
    Markman TM; Markman M
    F1000Res; 2019; 8():. PubMed ID: 30755794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
    Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
    Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity.
    Lang NN; Touyz RM
    Clin Sci (Lond); 2021 Dec; 135(23):2661-2663. PubMed ID: 34881389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
    Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
    Shiga T; Hiraide M
    Curr Treat Options Oncol; 2020 Mar; 21(4):27. PubMed ID: 32266582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adapting conventional cancer treatment for immunotherapy.
    Qiao J; Liu Z; Fu YX
    J Mol Med (Berl); 2016 May; 94(5):489-95. PubMed ID: 26910191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.
    Travers RJ; Stepanian A; Jaffe IZ
    Arterioscler Thromb Vasc Biol; 2024 Oct; 44(10):2143-2153. PubMed ID: 39145393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.
    Moudgil R; Yeh ET
    Can J Cardiol; 2016 Jul; 32(7):863-870.e5. PubMed ID: 27117975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
    Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
    Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
    Yeh ETH; Ewer MS; Moslehi J; Dlugosz-Danecka M; Banchs J; Chang HM; Minotti G
    Semin Oncol; 2019 Dec; 46(6):397-402. PubMed ID: 31753424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing cardio-oncology programs for cancer patients.
    Francis SA; Asnani A; Neilan T; Scherrer-Crosbie M
    Future Oncol; 2015; 11(14):2011-5. PubMed ID: 26198828
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
    Liang Z; He Y; Hu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.
    Yang X; Li G; Yang T; Guan M; An N; Yang F; Dai Q; Zhong C; Luo C; Gao Y; Das S; Xing Y; Shang H
    Oxid Med Cell Longev; 2020; 2020():4894625. PubMed ID: 33110473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.
    Klee NS; McCarthy CG; Martinez-Quinones P; Webb RC
    Ther Adv Cardiovasc Dis; 2017 Nov; 11(11):297-317. PubMed ID: 28911261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.
    Herrmann J
    Nat Rev Cardiol; 2020 Aug; 17(8):474-502. PubMed ID: 32231332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.